The government is making a new push into the biotechnology sector by investing in a company that will focus on the development of a drug for treating AIDS.
The state-owned National Development Fund (NDF) will pump in US$20 million to help establish a biotech firm to be called TaiMed Biologics, Council for Economic Planning and Development Chairwoman Ho Mei-yueh (何美玥) told a press conference yesterday.
The move is one of a package of government measures designed to turn the nation's biotech industry into a trillion-dollar sector, following in the footsteps of the foundry and display industries.
PHOTO: CHEN TSE-MING, TAIPEI TIMES
Of the NT$30 billion (US$907 million) budget the government plans to invest in the biotech sector, the state fund has directly invested NT$8 billion in 12 biotech companies, Ho said, adding that the government could pump in more capital to fuel the industry's growth even after the budget is expended.
The new biotech company will be chaired by former vice premier Tsai Ying-wen (
David Ho told the press conference that, although it was impossible to know whether the NDF would see significant returns from its investment in TaiMed Biologics, this kind of investment is needed to stimulate the industry.
TaiMed Biologics purchased the patent for the drug TNX-355, which was developed by US-based Genentech Inc, and plans to complete development of the drug, which blocks HIV from entering human cells, in three years.
After launching TNX-355 on the global market, TaiMed Biologics will devote itself to developing flu and bird flu vaccines, he said.
If TaiMed Biologics later establishes a plant to manufacture drugs or other medical products, the NDF would also finance that, Ho Mei-yueh said.
Inviting private enterprises to jointly invest in TaiMed Biologics, the CEPD chairwoman said she had a shortlist of possible investors and would first approach Terry Gou (郭台銘), chairman of Hon Hai Precision Industry Co (鴻海精密).
On Sept. 4, Gou announced he would donate NT$15 billion to National Taiwan University to fund biomedical engineering projects and the construction of a hospital for treating cancer.
In June, Gou, who leads the world's largest contract maker of electronic components, reportedly said he would donate NT$100 billion to fund cancer research by scientists in Taiwan and China.
"I will brief him [to try to win] his support for the company [TaiMed Biologics]," Ho Mei-yueh said.
To encourage development of the biotechnology and pharmaceutical industry, the legislature in June passed tthe Biotech and New Pharmaceutical Development Statute (
The new law stipulates that 35 percent of company investment in R&D and personnel training in the two sectors is tax-deductible for the next five years.
If a firm's expenditure on R&D and personnel exceeds its average spending in the previous two years, 50 percent of the extra amount is tax-deductible.
In addition, employees in the industries who receive stock options do not need to pay income tax on their shares.
Government researchers who get permission from the institute where they are employed can also cooperate with private companies to develop new drugs, while researchers can work as consultants at private companies.
TEMPORARY TRUCE: China has made concessions to ease rare earth trade controls, among others, while Washington holds fire on a 100% tariff on all Chinese goods China is effectively suspending implementation of additional export controls on rare earth metals and terminating investigations targeting US companies in the semiconductor supply chain, the White House announced. The White House on Saturday issued a fact sheet outlining some details of the trade pact agreed to earlier in the week by US President Donald Trump and Chinese President Xi Jinping (習近平) that aimed to ease tensions between the world’s two largest economies. Under the deal, China is to issue general licenses valid for exports of rare earths, gallium, germanium, antimony and graphite “for the benefit of US end users and their suppliers
Dutch chipmaker Nexperia BV’s China unit yesterday said that it had established sufficient inventories of finished goods and works-in-progress, and that its supply chain remained secure and stable after its parent halted wafer supplies. The Dutch company suspended supplies of wafers to its Chinese assembly plant a week ago, calling it “a direct consequence of the local management’s recent failure to comply with the agreed contractual payment terms,” Reuters reported on Friday last week. Its China unit called Nexperia’s suspension “unilateral” and “extremely irresponsible,” adding that the Dutch parent’s claim about contractual payment was “misleading and highly deceptive,” according to a statement
Nissan Motor Co has agreed to sell its global headquarters in Yokohama for ￥97 billion (US$630 million) to a group sponsored by Taiwanese autoparts maker Minth Group (敏實集團), as the struggling automaker seeks to shore up its financial position. The acquisition is led by a special purchase company managed by KJR Management Ltd, a Japanese real-estate unit of private equity giant KKR & Co, people familiar with the matter said. KJR said it would act as asset manager together with Mizuho Real Estate Management Co. Nissan is undergoing a broad cost-cutting campaign by eliminating jobs and shuttering plants as it grapples
The Chinese government has issued guidance requiring new data center projects that have received any state funds to only use domestically made artificial intelligence (AI) chips, two sources familiar with the matter told Reuters. In recent weeks, Chinese regulatory authorities have ordered such data centers that are less than 30 percent complete to remove all installed foreign chips, or cancel plans to purchase them, while projects in a more advanced stage would be decided on a case-by-case basis, the sources said. The move could represent one of China’s most aggressive steps yet to eliminate foreign technology from its critical infrastructure amid a
RSS